| 发明名称 |
BIOMARKERS FOR PSORIASIS TREATMENT RESPONSE |
| 摘要 |
Single nucleotide polymorphisms (SNPs) are provided that correlate with responsiveness of psoriasis patients to treatment with a therapeutic antibody that specifically binds to the p19 subunit of IL-23. The SNPs are used as biomarkers to prospectively selecting psoriasis patients likely to benefit from treatment with antagonists of IL-23, such as an antibody that specifically binds to the p19 subunit of IL-23. |
| 申请公布号 |
US2015322519(A1) |
申请公布日期 |
2015.11.12 |
| 申请号 |
US201314652229 |
申请日期 |
2013.12.19 |
| 申请人 |
MICELWEE Joshua;MOGG Robin;MEHROTRA Devan;MERCK SHARP & DOHME CORP. |
发明人 |
McElwee Joshua;Mogg Robin;Mehrotra Devan |
| 分类号 |
C12Q1/68;C07K16/24 |
主分类号 |
C12Q1/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of determining whether a psoriasis patient should be excluded from treatment with an antagonist of IL-23 comprising:
a) detecting which genotypes are present at one or more SNPs in the genome of the patient, wherein the SNPs are selected from the group consisting of:
i) SNP rs1876117;ii) SNP rs2048005;iii) SNP rs7690470;iv) SNP rs4106571; andv) SNP rs8073229,and b) excluding the patient from treatment with said IL-23 antagonist if (and only if) the patient has at least one genotype selected from the group consisting of:
i) rs1876117 (G/G);ii) rs2048005 (T/T);iii) rs7690470 (T/T);iv) rs4106571 (C/C); andv) rs8073229 (G/G). |
| 地址 |
Boston MA US |
